ELI LILLY AND COMPANY

(LLY)
  Report
Delayed Nyse  -  04:03 2022-08-18 pm EDT
316.72 USD   -0.03%
08/17Direct Relief Delivers Seven-Week Supply of Long-Acting Insulin to Ukraine, Donated by Lilly
AQ
08/16INSIDER BUY : Eli Lilly
MT
08/12ELI LILLY AND COMPANY : Ex-dividend day for
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 126 190153 067250 419301 034--
Enterprise Value (EV)1 139 069165 981263 395310 987307 109304 505
P/E ratio 14,8x24,9x45,1x44,7x36,4x27,5x
Yield 1,96%1,75%1,23%1,23%1,32%1,53%
Capitalization / Revenue 5,65x6,24x8,84x10,4x9,95x8,74x
EV / Revenue 6,23x6,76x9,30x10,8x10,2x8,84x
EV / EBITDA 18,4x19,3x26,3x31,5x27,2x21,8x
Price to Book 48,3x28,6x29,4x27,7x19,5x15,1x
Nbr of stocks (in thousands) 960 131906 582906 592950 175--
Reference price (USD) 131169276317317317
Announcement Date 01/30/202001/29/202102/03/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 22 32024 54028 31828 86030 25634 444
EBITDA1 7 5518 58910 0059 87211 30513 978
Operating profit (EBIT)1 6 0797 2658 4578 5149 77112 257
Operating Margin 27,2%29,6%29,9%29,5%32,3%35,6%
Pre-Tax Profit (EBT)1 5 2667 2306 1567 4918 96811 357
Net income1 8 3186 1945 5826 3757 70910 078
Net margin 37,3%25,2%19,7%22,1%25,5%29,3%
EPS2 8,896,796,127,098,7011,5
Dividend per Share2 2,582,963,403,904,184,84
Announcement Date 01/30/202001/29/202102/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 8 0007 8106 4886 9097 5736 594
EBITDA1 2 9823 0461 6792 5092 690-
Operating profit (EBIT)1 2 5362 6101 3302 0722 325-
Operating Margin 31,7%33,4%20,5%30,0%30,7%-
Pre-Tax Profit (EBT) ------
Net income1 1 7261 9039531 4531 806-
Net margin 21,6%24,4%14,7%21,0%23,8%-
EPS2 1,90-1,051,432,50-
Dividend per Share ------
Announcement Date 02/03/202204/28/202208/04/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 12 87912 91412 9769 9536 0743 471
Net Cash position1 ------
Leverage (Debt / EBITDA) 1,71x1,50x1,30x1,01x0,54x0,25x
Free Cash Flow1 3 8035 1125 9517 7588 0029 101
ROE (Net Profit / Equities) 89,6%175%102%71,7%70,9%71,2%
Shareholders' equity1 9 2893 5305 4878 89010 87714 147
ROA (Net Profit / Asset) 13,4%14,4%15,6%14,9%16,4%21,6%
Assets1 62 14342 96135 81642 85446 96246 751
Book Value Per Share2 2,725,909,4111,516,221,0
Cash Flow per Share2 5,177,127,969,629,9612,1
Capex1 1 0341 3881 3101 3081 3771 454
Capex / Sales 4,63%5,66%4,63%4,53%4,55%4,22%
Announcement Date 01/30/202001/29/202102/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 301 034 385 521
Net sales (USD) 28 318 400 000
Number of employees 35 000
Sales / Employee (USD) 809 097
Free-Float 99,7%
Free-Float capitalization (USD) 300 277 419 391
Avg. Exchange 20 sessions (USD) 931 580 094
Average Daily Capital Traded 0,31%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA